Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.

[1]  C. Dinarello,et al.  Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. , 1991, Blood.

[2]  W. Arend,et al.  IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. , 1991, Journal of immunology.

[3]  C. Dinarello,et al.  Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. , 1991, The Journal of biological chemistry.

[4]  S. N. Vogel,et al.  Roles of interleukin-1 and tumor necrosis factor in lipopolysaccharide-induced hypoglycemia , 1991, Infection and immunity.

[5]  D. Dripps,et al.  Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. , 1991, The Journal of biological chemistry.

[6]  C. Dinarello,et al.  Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. , 1991, The Journal of clinical investigation.

[7]  C. Dinarello.  Interleukin-1 and interleukin-1 antagonism. , 1991, Blood.

[8]  J. Norton,et al.  A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice , 1991, The Journal of experimental medicine.

[9]  K. McIntyre,et al.  Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody , 1991, The Journal of experimental medicine.

[10]  C. Dinarello,et al.  A specific receptor antagonist for interleukin 1 prevents Escherichia coli‐induced shock in rabbits , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  S. N. Vogel,et al.  An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance , 1991, Infection and immunity.

[12]  R. Thompson,et al.  The intratracheal administration of endotoxin and cytokines. III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin- and IL-1-induced acute inflammation. , 1991, The American journal of pathology.

[13]  C. Dinarello,et al.  Interleukin-1 augments gamma-aminobutyric acidA receptor function in brain. , 1991, Molecular pharmacology.

[14]  J. Klein-Nulend,et al.  Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. , 1990, Journal of immunology.

[15]  T. Barbui,et al.  Expression of leukocyte alkaline phosphatase gene in normal and leukemic cells: regulation of the transcript by granulocyte colony-stimulating factor. , 1990, Blood.

[16]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.

[17]  A. Abbas,et al.  Heterogeneity of helper/inducer T lymphocytes. III. Responses of IL-2- and IL-4-producing (Th1 and Th2) clones to antigens presented by different accessory cells. , 1990, Journal of immunology.

[18]  D. Roeder,et al.  Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer. , 1990, Science.

[19]  H. Starnes,et al.  Preliminary report: effects of interleukin-1 on platelet counts , 1990, The Lancet.

[20]  C. Nast,et al.  Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. , 1990, The Journal of clinical investigation.

[21]  O. Ramilo,et al.  Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation , 1990, The Journal of experimental medicine.

[22]  J. Griffin,et al.  Demonstration of interleukin-1 beta transcripts in acute myeloblastic leukemic cells by in situ hybridization. , 1990, Leukemia.

[23]  R. Thompson,et al.  Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. , 1990, The Journal of clinical investigation.

[24]  S. Jobling,et al.  A point mutation uncouples human interleukin-1 beta biological activity and receptor binding. , 1990, The Journal of biological chemistry.

[25]  C. J. Dunn,et al.  Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein , 1990, Nature.

[26]  M. T. Brewer,et al.  Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist , 1990, Nature.

[27]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor , 1990, Nature.

[28]  C. Dinarello,et al.  Interleukin-2 production is suppressed by dietary N-3 fatty acids but enhanced by oral aspirin , 1989 .

[29]  C. Hannum,et al.  An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties. , 1989, Journal of immunology.

[30]  J. McCubrey,et al.  The interleukin-1 receptor in Raji human B-lymphoma cells. Molecular characterization and evidence for receptor-mediated activation of gene expression. , 1989, The Biochemical journal.

[31]  C. Wollheim,et al.  A natural interleukin 1 (IL-1) inhibitor counteracts the inhibitory effect of IL-1 on insulin production in cultured rat pancreatic islets. , 1989, Journal of autoimmunity.

[32]  J. Larrick.  Native interleukin 1 inhibitors. , 1989, Immunology today.

[33]  D. Boraschi,et al.  Differential binding of IL‐ 1α and IL‐ 1β to receptors on B and T cells , 1989 .

[34]  C. Dinarello,et al.  Interleukin 1-dependent paracrine granulopoiesis in chronic granulocytic leukemia of the juvenile type. , 1988, The Journal of clinical investigation.

[35]  C. March,et al.  cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. , 1988, Science.

[36]  C. Griscelli,et al.  SPECIFIC INTERLEUKIN-1 INHIBITOR IN SERUM AND URINE OF CHILDREN WITH SYSTEMIC JUVENILE CHRONIC ARTHRITIS , 1987, The Lancet.

[37]  J. Lowenthal,et al.  A urine inhibitor of interleukin 1 activity that blocks ligand binding. , 1987, Journal of immunology.

[38]  J. Dayer,et al.  Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). , 1986, The Journal of clinical investigation.

[39]  J. Nerup,et al.  Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. , 1986, Science.

[40]  W. Arend,et al.  Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. , 1985, Journal of immunology.

[41]  J. Chin,et al.  Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. , 1991, Arthritis and rheumatism.

[42]  G. Duff,et al.  Interleukin 1: the first interleukin. , 1990, Immunology today.

[43]  K. Bendtzen,et al.  Autoantibodies to cytokines--friends or foes? , 1990, Immunology today.

[44]  C. Dinarello,et al.  An overview on interleukin-1 as a therapeutic agent , 1989, Biotherapy.

[45]  R. Cohen,et al.  Interleukin 1 inhibits contraction of vascular smooth muscle. , 1989, The Journal of clinical investigation.

[46]  V. Barak,et al.  Interleukin 1 inhibitory activity secreted by a human myelomonocytic cell line (M20) , 1986, European journal of immunology.

[47]  P. Lomedico,et al.  Cloning and expression of murine interleukin-1 cDNA in Escherichia coli , 1984, Nature.